• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

HemaQuest Pharmaceuticals

edit

HemaQuest is a Seattle-based biopharmaceutical company developing proprietary small molecules targeting specific genes that enable the treatment of serious and life threatening hematologic disorders. As of April 2010, the Company has two therapeutics in Phase 2 clinical development - HQK-1001 for hemoglobin disorders, such as sickle cell disease, and HQK-1004 for viral-related cancers. It was founded in late 2007 by leading hematologists with funding from top tier investors, including De Novo Ventures, Forward Ventures, and Lilly Ventures.

Recent Milestones

edit

• 
  HemaQuest Pharmaceuticals received $13M in Series B funding. (3/12/12)
  Posted 3/12/12 at 7:53pm via hemaquest.com
• 
  HemaQuest Pharmaceuticals received $12M in Series B funding. (4/21/10)
  Posted 4/21/10 at 6:35pm via fiercebiotech.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 3/13/12

Sources

1. HemaQuest books $12M Series B to advance mid-stage programs (fiercebiotech.com) [edit]
2. HemaQuest Pharmaceuticals Raises $13 Million in Series B Extension Financing (hemaquest.com) [edit]